BRMS1 is a transcriptional repressor that functions as a metastasis suppressor through multiple epigenetic and signaling mechanisms. Primary function: BRMS1 inhibits NF-κB-mediated transcription by promoting HDAC1-dependent deacetylation of RELA at lysine 310, thereby downregulating anti-apoptotic genes 1. BRMS1 associates with SIN3 chr11 remodeling complexes to regulate transcription of metastasis-promoting genes 1. Mechanism: Beyond transcriptional repression, BRMS1 regulates focal adhesion kinase (FAK), epidermal growth factor receptor (EGFR), and NF-κB pathways, and promotes anoikis—apoptosis of inadequately adherent cells—thereby inhibiting metastatic spread 2. BRMS1 suppresses angiogenesis by inhibiting NF-κB-dependent IL-6 expression 3. Disease relevance: Reduced BRMS1 expression correlates with metastatic progression in breast cancer, melanoma, and rectal cancer 435. Clinical significance: BRMS1 expression serves as an independent prognostic marker for patient outcomes and disease-specific survival, with downregulation strongly associated with tumor-node-metastasis stage and metastatic capacity 43. BRMS1 promoter shows utility for cancer-specific gene therapy applications 6.